Bastiano Sanna - May 2, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 2, 2023
Transactions value $
-$1,544,187
Form type
4
Date filed
5/4/2023, 04:51 PM
Previous filing
Apr 14, 2023
Next filing
May 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$494K -1.41K -3.55% $350.32 38.3K May 2, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$14.8K -42 -0.11% $351.65 38.3K May 2, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$59.7K -169 -0.44% $353.24 38.1K May 2, 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale -$719K -2.05K -5.39% $350.44 36K May 3, 2023 Direct F1, F2, F6
transaction VRTX Common Stock Sale -$256K -728 -2.02% $351.60 35.3K May 3, 2023 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $350.32 (range $350.00 to $350.92).
F4 Open market sales reported on this line occurred at a weighted average price of $351.65 (range $351.48 to $351.80).
F5 Open market sales reported on this line occurred at a weighted average price of $353.24 (range $353.21 to $353.49).
F6 Open market sales reported on this line occurred at a weighted average price of $350.44 (range $350.00 to $350.94).
F7 Open market sales reported on this line occurred at a weighted average price of $351.60 (range $351.01 to $352.00).